Predictive value of various parameters for the antihypertensive effect of the beta blocker ICI 66,082 (1)
- PMID: 238480
Predictive value of various parameters for the antihypertensive effect of the beta blocker ICI 66,082 (1)
Abstract
The antihypertensive effect of the new beta-blocker, ICI 66,082 was studied in 37 patients with renal or essential hypertension. A daily dose of 75 mg produced a significant antihypertensive effect and a further blood pressure decrease was obtained by increasing the daily dose up to 300 mg; at this treatment level, the antihypertensive effect averaged 29.4/24.0 mm Hg. Increasing the dose from 300 to 600 mg daily did not produce a significant additional blood pressure decrease. Six of the 37 patients retained fluid, producing a loss in the antihypertensive effect. No significant correlation was found between the percentage systolic blood pressure fall and the following parameters determined before therapy: systolic blood pressure and its variability, heart rate (at rest and after stimulation by exercise or isoproterenol), cardiac output and total peripheral resistance, renin concentration (at rest and after stimulation) and urinary excretion of catecholamines and derivates.
Similar articles
-
[Haemodynamic response to antihypertensive treatment with atenolol in patients with hypertension (author's transl].Wien Klin Wochenschr. 1978 Sep 1;90(16):611-6. Wien Klin Wochenschr. 1978. PMID: 695651 German.
-
Does beta 1-selective agonistic activity interfere with the antihypertensive efficacy of beta 1-selective blocking agents?J Hypertens Suppl. 1985 Dec;3(3):S243-5. J Hypertens Suppl. 1985. PMID: 2908819 Clinical Trial.
-
Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade.Clin Pharmacol Ther. 1998 Nov;64(5):522-35. doi: 10.1016/S0009-9236(98)90135-7. Clin Pharmacol Ther. 1998. PMID: 9834044 Clinical Trial.
-
Clinical and hemodynamic effects of celiprolol in essential hypertension.J Cardiovasc Pharmacol. 1989;14 Suppl 7:S14-21. J Cardiovasc Pharmacol. 1989. PMID: 2481785 Review.
-
Overview of clinical safety and efficacy of tertatolol.Cardiology. 1993;83 Suppl 1:41-50. doi: 10.1159/000176009. Cardiology. 1993. PMID: 7903214 Review.
Cited by
-
The management of hypertension.Br J Clin Pharmacol. 1986;21 Suppl 2(Suppl 2):129S-142S. doi: 10.1111/j.1365-2125.1986.tb02862.x. Br J Clin Pharmacol. 1986. PMID: 3530297 Free PMC article. Review. No abstract available.
-
Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.Drugs. 1979 Jun;17(6):425-60. doi: 10.2165/00003495-197917060-00001. Drugs. 1979. PMID: 38096 Review.
-
Hypertension: which beta-blocker?Drugs. 1976 Dec;12(6):412-14. doi: 10.2165/00003495-197612060-00002. Drugs. 1976. PMID: 11985 Review. No abstract available.
-
Influence of metoprolol, alone and in combination with a thiazide diuretic, on blood pressure, plasma volume, extracellular volume and glomerular filtration rate in essential hypertension.Eur J Clin Pharmacol. 1979 Jun 12;15(5):305-10. doi: 10.1007/BF00558432. Eur J Clin Pharmacol. 1979. PMID: 378672 Clinical Trial. No abstract available.
-
The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.Br J Clin Pharmacol. 1978 May;5(5):379-99. doi: 10.1111/j.1365-2125.1978.tb01644.x. Br J Clin Pharmacol. 1978. PMID: 26370 Free PMC article. Review.